Atherosclerosis Risk in Communities [156], CSF metabolomics [157,158], and even commercial laboratories such as ARUP. These incremental advances have been accompanied by calls for greater methodological transparency, but adherence to these calls waxes and wanes in the absence of a mandate. As rigor...